Retatrutide vs Tirzepatide

A research-use structural comparison covering receptor targets in the literature, molecular class and lyophilised format.

Retatrutide and tirzepatide are two synthetic, lipid-modified peptides of similar size that were developed by the same originator and that act on overlapping sets of incretin-family receptors. This page is a structural and classification reference for qualified researchers. It compares molecular class, the receptor targets described in the published literature, regulatory context and the lyophilised research format. It makes no claims about effects, safety or use.

1. At a glance

	Retatrutide	Tirzepatide
Molecular class	Synthetic, lipid-conjugated peptide	Synthetic, lipid-conjugated peptide
Length	39 amino acids	39 amino acids
Lipid modification	Fatty diacid attached through a linker	C20 fatty diacid attached through a linker to a lysine
Receptors described in the literature	GIP, GLP-1 and glucagon (triple agonist)	GIP and GLP-1 (dual agonist)
Research code	LY3437943	LY3298176
CAS number	2381089-83-2	2023788-19-2
Approximate molecular weight	About 4.7 kDa	About 4.8 kDa
Regulatory status (see Section 2)	Investigational	Active ingredient in FDA-approved prescription medicines
Trinity Research format	Lyophilised research material, sealed vial	Lyophilised research material, sealed vial

Molecular weights are approximate and are shown for orientation only. The figures that apply to your material are those on the Certificate of Analysis for your lot.

2. Regulatory context

Tirzepatide is the active ingredient of prescription medicines that have been approved by the U.S. Food and Drug Administration and are made by a licensed manufacturer. Material supplied by Trinity Research is a separate laboratory research material. It is not those medicines, has not been evaluated by the FDA, and is not for human or veterinary use.
Retatrutide is an investigational compound. As of the date of this page it has not been approved for any use by the FDA or by any other major regulator, and it remains the subject of ongoing clinical development by its originator. Regulatory status can change, so please check current primary sources.

Nothing on this page should be read as encouraging or supporting the human use of any research material. Anyone with a medical question should speak to a licensed healthcare professional.

3. Molecular structure

Both molecules are 39-residue peptides with a lipid side chain. That side chain is a fatty diacid, joined through a linker to an amino-acid residue, and it is the feature that gives these compounds a long-acting profile in the literature. Both also carry non-natural amino-acid residues in their sequences, which are described in the published structures as stabilising the peptide.

The main structural difference lies in the sequence and in the combination of residues that shape how each peptide is described as interacting with the receptor family. Retatrutide’s published description includes activity at the glucagon receptor in addition to the two incretin receptors. Because the two peptides are close in size and share their overall design, they are a useful pair for illustrating why a report needs both HPLC and mass spectrometry: an identity result confirms which of the two you actually have. See our guide on how HPLC and mass spectrometry verify peptides.

4. Receptor targets in the literature

Receptor	Retatrutide	Tirzepatide
GIP receptor	Described as an agonist	Described as an agonist
GLP-1 receptor	Described as an agonist	Described as an agonist
Glucagon receptor	Described as an agonist	Not described as a target

The table lists the receptors that the published literature identifies as targets of each molecule. It is a classification, not a comparison of potency, and it does not describe any biological or clinical outcome. Readers interested in the underlying pharmacology should consult the primary literature and the originator’s published documents directly.

5. The lyophilised research format

Trinity Research supplies both compounds as lyophilised powders in sealed vials, each with a lot-specific Certificate of Analysis. The format is a research-material format: it is chosen because dry, sealed material is more stable than material in solution, and it makes traceability simple. It is not a presentation for human or veterinary use. For handling notes on sealed material, see our guide on handling and storing lyophilised research material.

6. What to check on the COA

The lot number on the report matches the one on your vial. See lot numbers and traceability.
The compound name on the report is the one you ordered. The two peptides here are easy to mix up in paperwork.
Identity is reported by mass spectrometry, with an observed mass close to the theoretical mass for that compound.
Purity is reported by HPLC, with the method stated.
Only what is listed was tested. Do not assume other tests were run.

If you need help reading a report, see our guide on how to read a Certificate of Analysis.

7. What this comparison does not cover

This page does not compare effects, outcomes, safety or tolerability, and it gives no information on doses, preparation or administration. Trinity Research does not provide dosing, reconstitution, administration, clinical, medical, veterinary or treatment guidance of any kind. Values on this page are given for identification and reference, and they may be updated as the literature and regulatory position change.